Amphotericin B still in the headlines

Pathogens and Global Health

Volumn 106, Issue 2, 2012, Pages 80-81

  Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CHOLESTEROL; ERGOSTEROL; POLYENE;

ANEMIA; ANTIMICROBIAL THERAPY; CANCER PATIENT; CANDIDIASIS; DRUG EFFICACY; HEART ARRHYTHMIA; HUMAN; NEPHROTOXICITY; NOTE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FUNGI; HUMANS; MYCOSES;

EID: 84865109959     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/204777312X13419245939566     Document Type: Note

References (5)

1. Odds FC Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11:272-9.
2. Sanglard D, White TC. Molecular principles of antifungal drug resistance. In: Heitman J, Filler SG, Edwards JE, Mitchell AP (eds.), Molecular principles of fungal pathogenesis. Washington, DC: ASM Press, 2007;197-212.
3. Ostroumova OS, Efimova SS, Schagina LW. Probing Amphotericin B Single channel activity by membrane dipole modifiers. PLoS One. 2012;7(1):e30261.
4. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, Burke MD. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci USA. 2012;10:2234-9.
5. te Welscher YM, Jones L, van Leeuwen MR, Dijksterhuis J, de Kruijff B, Eitzen G, Breukink E. Natamycin inhibits vacuole fusion at the priming phase via a specific interaction with ergosterol. Antimicrob Agents Chemother. 2010;54:2618-25